Patents Assigned to Kentucky BioProcessing, Inc.
-
Publication number: 20210236624Abstract: Disclosed herein are methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).Type: ApplicationFiled: February 26, 2021Publication date: August 5, 2021Applicant: Kentucky BioProcessing, Inc.Inventors: Steven D. Hume, Leigh Burden, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, Youngjun Oh, John W. Shepherd, Michael H. Pauly
-
Publication number: 20210017502Abstract: Disclosed herein are methods and exemplary compositions associated with antigen purification, exemplary aspects of which may include harvesting viral and antigenic substances from source organisms; and a purification platform comprising chemical separation and size-difference separation for the removal of contaminants, debris and impurities from the viral and protein (e.g. antigenic, including influenza hemagglutinin antigens) substances, as well as their concentration and collection.Type: ApplicationFiled: October 5, 2020Publication date: January 21, 2021Applicant: Kentucky BioProcessing, Inc.Inventors: Steven D. Hume, Leigh Burden, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, John W. Shepherd, Kelsi Swope
-
Publication number: 20210000942Abstract: Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).Type: ApplicationFiled: July 2, 2020Publication date: January 7, 2021Applicant: Kentucky BioProcessing, Inc.Inventors: Steven D. Hume, Leigh Burden, Joshua Morton, Greg Pogue, Barry Bratcher, Hugh A. Haydon, Carrie A. Simpson, Nick Partain, Youngjun Oh, John W. Shepherd, Michael H. Pauly
-
Publication number: 20170313999Abstract: A new, reliable, easily scalable and reproducible method for the production of recombinant butyrylcholinesterase (rBuChE) is provided. Through the utilization of a plant transfection procedure, various plant strains have been shown to generate effective and scalable amounts of rBuChE under acceptable manufacturing processes to permit reliable levels of such enzymes for desired nerve agent protection requirements (including tetrameric products). As well, such methods in engineered plant lines have shown suitable production of these enzymes in tetramer form with glycan formation and sialylation (for terminal groups) to allow for optimal potency against organophosphorus agent exposure as well as proper immunogenic response within the plant sources. The overall production method, including the transfection and production within mammalian cells, as well as the process steps involved for such a reliable sourcing platform from plants is thus encompassed within the invention.Type: ApplicationFiled: May 23, 2017Publication date: November 2, 2017Applicant: Kentucky BioProcessing, Inc.Inventors: Greg Pogue, Ernie Hiatt, Romy Kandzia, Stefan Werner, Frank Thieme, Tsafrir Mor, Steven Hume
-
Patent number: 9688970Abstract: A new, reliable, easily scalable and reproducible method for the production of recombinant butyrylcholinesterase (rBuChE) is provided. Through the utilization of a plant transfection procedure, various plant strains have been shown to generate effective and scalable amounts of rBuChE under acceptable manufacturing processes to permit reliable levels of such enzymes for desired nerve agent protection requirements (including tetrameric products). As well, such methods in engineered plant lines have shown suitable production of these enzymes in tetramer form with glycan formation and sialyalation (for terminal groups) to allow for optimal potency against organophosphorus agent exposure as well as proper immunogenic response within the plant sources. The overall production method, including the transfection and production within mammalian cells, as well as the process steps involved for such a reliable sourcing platform from plants is thus encompassed within the invention.Type: GrantFiled: July 31, 2014Date of Patent: June 27, 2017Assignee: Kentucky BioProcessing, Inc.Inventors: Greg Pogue, Ernie Hiatt, Romy Kandzia, Stefan Werner, Frank Thieme, Tsafrir Mor, Steven Hume